|
|
|
|
|||||
|
|
|
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on July 24, reiterating a Buy rating on the stock with an $850 price target.
The firm stated that it anticipates weakness to continue in EYLEA sales for Q2 2025, primarily because of biosimilar competition and continued co-pay assistance shortfalls.
Canaccord further said that it is on the lookout for updates from the pipeline (Factor XI, Obesity) to point to potential upside in the second half of 2025.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.
While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 9 hours | |
| 17 hours | |
| Jul-27 | |
| Jul-25 | |
| Jul-25 | |
| Jul-25 | |
| Jul-25 | |
| Jul-24 | |
| Jul-24 | |
| Jul-24 | |
| Jul-24 | |
| Jul-24 | |
| Jul-24 | |
| Jul-23 | |
| Jul-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite